AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$KMDA

Tsur David sold $1.5M of KMDA

Tsur David sold 177,173 shares of KAMADA LTD (KMDA) at an average of $8.26 ($8.26–$8.28, $1.46M total) across 3 trades over 2026-09-07 to 2026-09-09.

Original reporting
SEC EDGAR · Tsur David
Published Sep 11, 2026, 3:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 3:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KMDA
Bearish
high confidence
Mentioned
$KMDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMDABearishMed
01

Why it matters

The director's sale reduces his ownership, which could be interpreted by investors as a lack of confidence.

02

Market read

Insider sale of $1.5M may influence short-term trading decisions on KMDA.

03

What to watch

Sale was executed over three days at consistent price, possibly part of a pre-arranged plan.

Relevance 6/10Novelty 8/10Timing: Filed Sep 11, covering trades from Sep 7-9

Background

Form 4 filing reports insider transactions required by SEC.

Company-level read

Ticker impact

$KMDABearishHigh confidence
Context

Director Tsur David sold 177,173 shares for $1.46M, reducing his stake to 430,756 shares.

Expected impact

Potential short-term downside pressure.

Evidence & confidence

Large insider sale ($1.5M) by a director often precedes price weakness.

Market effects

Sector

May affect biotech sector sentiment as insider sales are watched closely.

Regional

Limited to US and Israeli markets where KMDA trades.

Global

Low global impact, confined to the stock.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily indicate company issues.

Key entities

  • Company
    Kamada Ltd

    Biotech company listed on Nasdaq (KMDA).

  • Insider
    Tsur David

    Director of Kamada Ltd.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KMDA insider trading history →

Related articles

AUG 19
$KMDAMed

Kamada (KMDA) Q2 2026 Earnings Call Transcript

Kamada reported Q2 2026 earnings with record revenues of $54.9M (+23% YoY) and adjusted EBITDA of $14.1M (+29% YoY). The company reiterated its 2026 guidance of $200M-$205M in revenues and $50M-$53M in adjusted EBITDA. Growth is driven by existing products, with plans to accelerate through acquisitions and expanded distribution. Key products like KEDRAB and GLASSIA showed strong demand, and the company expects plasma sales to begin by year-end.

yahoo.com2 min
AUG 12
$KMDAMed

Kamada Ltd. Q2 2026 Earnings Call Summary

Kamada Ltd. reported Q2 2026 results driven by double-digit growth in its commercial portfolio, led by KEDRAB. Management reiterated 2026 revenue guidance of $200 million to $205 million and a 26% adjusted EBITDA margin. It expects plasma sales to start in Q4, supported by a 3-year $50 million supply deal, plus biosimilar expansion and M&A. CFO Chaime Orlev will leave end-2026.

yahoo.com6 min
AUG 12
$KMDAHighAI 9/10

Kamada Ltd.: Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Gui

Kamada Ltd. (NASDAQ: KMDA) reported record first-half 2026 results: revenues $100.2M (+13% YoY) and adjusted EBITDA $25.7M (+14% YoY), with net income $13.4M (+18%). Q2 revenues were $54.9M (+23%) and adjusted EBITDA $14.1M (+29%). It affirmed 2026 guidance: revenues $200M-$205M and adjusted EBITDA $50M-$53M, and signed a ~3-year ~$50M plasma supply agreement.

finanznachrichten.de6 min
AUG 12
$KMDAMed

KAMADA LTD (KMDA): Financial results for H1 2026

KAMADA LTD (KMDA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Kamada Reports Record-High First Half and Second Quarter 2026 Financial Results, Representing Double-Digit Profitable Growth and the Strongest in Kamada's History; Affirms 2026 Annual Guidance ● Record-High First Half Revenues of $100.2 Million, up 13% Year-over-Year

SEC EDGAR 6-K2 min
JUL 20
$KMDAMedAI 8/10

Kamada jumps on $50m source plasma deal

Kamada (Nasdaq: KMDA; TASE: KMDA) said it signed a three-year normal source plasma supply agreement with a biopharmaceutical company. The deal is expected to generate about $50 million in revenue over three years, with initial commercial sales recorded in Q4 2026. Kamada noted its Texas collection centers are ramping to support the supply.

globes.co.il2 min